Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)

Robert C. Whorf, John D. Hainsworth, David R. Spigel, DA Yardley, Howard A. Burris, David Waterhouse, E. R. Vazquez, F. Anthony Greco

Journal of Clinical Oncology · 2008 · 73 citations · 0 references

Concepts

Abstract

5010 Background: Recent use of anti-angiogenesis agents and m-TOR inhibitors has improved the treatment of patients (pts) with advanced RCC. In this multicenter phase II trial, we evaluated the efficacy and safety of a combination of bevacizumab (VEGF inhibitor) and RAD001 (m-TOR inhibitor) in pts with metastatic RCC. Methods: Pts with metastatic or unresectable locally recurrent clear cell RCC, ECOG PS 0 or 1, were eligible. 2 groups of pts were enrolled, based on previous treatment: Group A, no previous treatment with sorafenib or sunitinib; Group B, previous treatment with sorafenib and/or sunitinib. All pts received bevacizumab 10mg/kg IV every 2 weeks and RAD001 10mg PO daily. Pts were reevaluated after 8 weeks of treatment; pts with objective response/stable disease continued treatment with reevaluations every 8 weeks until progression. Results: Between July 2006 and November 2007, 59 pts (30 Group A, 29 Group B) were enrolled. The median age was 65 years; 76% had intermediate Motzer prognostic scores, and 43 pts (73%) had undergone previous nephrectomy. 42 pts (71%) received at least 8 weeks of treatment and were reevaluated; 6 pts were inevaluable (toxicity, 4; rapid progression, 1; intercurrent illness) and 11 are too early. 90% of pts who completed 8 weeks of treatment had objective response (21%) or minor response/stable disease (69%). Efficacy in Groups A and B is compared in the table below. Grade 3/4 proteinuria occurred in 10 pts (19%); other grade 3/4 toxicity was uncommon (fatigue 9%, stomatitis 8%). Grade 1/2 toxicities were common including fatigue (68%), skin rash/pruritus (55%), mucositis/stomatitis (49%), hyperlipidemia (45%), nausea (40%), hypertension (25%). Conclusions: The combination of bevacizumab + RAD001 is active and tolerable treatment for metastatic clear cell RCC. The combination has activity in pts previously treated with sorafenib and/or sunitinib. Better definition of the efficacy of this combination versus single-agent therapy requires comparative trials. Efficacy in Groups A and B Group A (N=30) Group B (N=18) Partial response 7 (23%) 2 (11%) Minor response (tumor reduction 10–30%) 13 (43%) 5 (28%) Stable 3 (10%) 8 (44%) Progression 2 (7%) 2 (11%) Unevaluable 5 (17%) 1 (6%) Median PFS 9 months 6 months Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer, Genentech, Novartis Genentech, Novartis Bristol-Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, GPC Biotech, Novartis, sanofi-aventis